

## CADTH RAPID RESPONSE REPORT: REFERENCE LIST

# Screening Strategies for the Detection of *Chlamydia Trachomatis* and/or *Neisseria Gonorrhoeae* during Pregnancy: Clinical Utility, Safety, and Cost-Effectiveness

Service Line:	Rapid Response Service
Version:	1.0
Publication Date:	June 29, 2020
Report Length:	7 Pages

**Authors:** Shannon Hill, Melissa Walter

**Cite As:** *Screening Strategies for the Detection of Chlamydia Trachomatis and/or Neisseria Gonorrhoeae during Pregnancy: Clinical Utility, Safety, and Cost-Effectiveness*. Ottawa: CADTH; 2020 Jun. (CADTH rapid response report: reference list).

**Disclaimer:** The information in this document is intended to help Canadian health care decision-makers, health care professionals, health systems leaders, and policy-makers make well-informed decisions and thereby improve the quality of health care services. While patients and others may access this document, the document is made available for informational purposes only and no representations or warranties are made with respect to its fitness for any particular purpose. The information in this document should not be used as a substitute for professional medical advice or as a substitute for the application of clinical judgment in respect of the care of a particular patient or other professional judgment in any decision-making process. The Canadian Agency for Drugs and Technologies in Health (CADTH) does not endorse any information, drugs, therapies, treatments, products, processes, or services.

While care has been taken to ensure that the information prepared by CADTH in this document is accurate, complete, and up-to-date as at the applicable date the material was first published by CADTH, CADTH does not make any guarantees to that effect. CADTH does not guarantee and is not responsible for the quality, currency, propriety, accuracy, or reasonableness of any statements, information, or conclusions contained in any third-party materials used in preparing this document. The views and opinions of third parties published in this document do not necessarily state or reflect those of CADTH.

CADTH is not responsible for any errors, omissions, injury, loss, or damage arising from or relating to the use (or misuse) of any information, statements, or conclusions contained in or implied by the contents of this document or any of the source materials.

This document may contain links to third-party websites. CADTH does not have control over the content of such sites. Use of third-party sites is governed by the third-party website owners' own terms and conditions set out for such sites. CADTH does not make any guarantee with respect to any information contained on such third-party sites and CADTH is not responsible for any injury, loss, or damage suffered as a result of using such third-party sites. CADTH has no responsibility for the collection, use, and disclosure of personal information by third-party sites.

Subject to the aforementioned limitations, the views expressed herein do not necessarily reflect the views of Health Canada, Canada's provincial or territorial governments, other CADTH funders, or any third-party supplier of information.

This document is prepared and intended for use in the context of the Canadian health care system. The use of this document outside of Canada is done so at the user's own risk.

This disclaimer and any questions or matters of any nature arising from or relating to the content or use (or misuse) of this document will be governed by and interpreted in accordance with the laws of the Province of Ontario and the laws of Canada applicable therein, and all proceedings shall be subject to the exclusive jurisdiction of the courts of the Province of Ontario, Canada.

The copyright and other intellectual property rights in this document are owned by CADTH and its licensors. These rights are protected by the Canadian *Copyright Act* and other national and international laws and agreements. Users are permitted to make copies of this document for non-commercial purposes only, provided it is not modified when reproduced and appropriate credit is given to CADTH and its licensors.

**About CADTH:** CADTH is an independent, not-for-profit organization responsible for providing Canada's health care decision-makers with objective evidence to help make informed decisions about the optimal use of drugs, medical devices, diagnostics, and procedures in our health care system.

**Funding:** CADTH receives funding from Canada's federal, provincial, and territorial governments, with the exception of Quebec.

Questions or requests for information about this report can be directed to [requests@cadth.ca](mailto:requests@cadth.ca)

## Research Questions

1. What is the clinical utility of different screening strategies for the detection of *Chlamydia trachomatis* (CT) and/or *Neisseria gonorrhoeae* (GC) during pregnancy?
2. What is the clinical evidence for the safety of different screening strategies for the detection of CT and/or GC during pregnancy?
3. What is the cost-effectiveness of different screening strategies for the detection of CT and/or GC during pregnancy?

## Key Findings

Three non-randomized studies were identified regarding the clinical utility of different screening strategies for the detection of *Chlamydia trachomatis* and/or *Neisseria gonorrhoeae* during pregnancy. No relevant studies were identified regarding the clinical evidence for the safety of different screening strategies for the detection of *Chlamydia trachomatis* and/or *Neisseria gonorrhoeae* during pregnancy. Additionally, no economic evaluations were identified regarding the cost-effectiveness of different screening strategies for the detection of *Chlamydia trachomatis* and/or *Neisseria gonorrhoeae* during pregnancy.

## Methods

A limited literature search was conducted by an information specialist on key resources including MEDLINE, Embase, the Cochrane Library, the University of York Centre for Reviews and Dissemination (CRD) databases, the websites of Canadian and major international health technology agencies, as well as a focused internet search. The search strategy was comprised of both controlled vocabulary, such as the National Library of Medicine's MeSH (Medical Subject Headings), and keywords. The main search concepts were testing, pregnancy, and chlamydia or gonorrhea. No filters were applied to limit the retrieval by study type. Where possible, retrieval was limited to the human population. The search was also limited to English language documents published between January 1, 2018 and June 22, 2020. Internet links were provided, where available.

## Selection Criteria

One reviewer screened citations and selected studies based on the inclusion criteria presented in Table 1.

**Table 1: Selection Criteria**

<b>Population</b>	Adults and adolescents who are pregnant (≥ 12 years of age, up to and including delivery)
<b>Intervention</b>	<p>A screening strategy for <i>Chlamydia trachomatis</i> and/or <i>Neisseria gonorrhoeae</i>, with or without clinical management of the confirmed infection.</p> <ul style="list-style-type: none"> <li>• Testing for CT using nucleic acid amplification test on urine, vaginal, or cervical samples</li> <li>• Testing for GC on NAAT using urine, vaginal, or cervical samples, or cultures using urethral or endocervical samples</li> </ul>
<b>Comparator</b>	<ul style="list-style-type: none"> <li>• An alternative screening strategy conducted with an alternative test, specimen, approach, timing, with a different frequency, or with any subsequent management strategy for pregnant persons with confirmed infection (including no management)</li> </ul>

	<ul style="list-style-type: none"> <li>No screening strategy</li> </ul>
<b>Outcomes</b>	<p>Q1. Clinical utility (e.g., detection yield outcomes, people who obtain screening in accordance with guidelines, adverse gynecological outcomes, adverse neonatal outcomes, patients receiving treatment for infection, prophylactic antibiotics for their offspring)</p> <p>Q2. Harms from undergoing screening (e.g., anxiety, adverse pregnancy outcomes, negative impacts of false-positive or false-negative results)</p> <p>Q3. Cost-effectiveness (e.g., cost per quality-adjusted life years, cost per benefit gained, cost per clinical outcome)</p>
<b>Study Designs</b>	Health technology assessments, systematic reviews, randomized controlled trials, non-randomized studies, economic evaluations

CT = *Chlamydia trachomatis*; GC = *Neisseria gonorrhoeae*; NAAT = nucleic acid amplification test.

## Results

Three non-randomized studies<sup>1-3</sup> were identified regarding the clinical utility of different screening strategies for the detection of CT and/or GC during pregnancy. No relevant health technology assessments, systematic reviews, randomized controlled trials, or economic evaluations were identified.

Additional references of potential interest that did not meet the inclusion criteria are provided in the appendix.

### Health Technology Assessments

No literature identified.

### Systematic Reviews and Meta-analyses

No literature identified.

### Randomized Controlled Trials

No literature identified.

### Non-Randomized Studies

#### *Clinical Utility*

- Gadoth A, Shannon CL, Hoff NA, et al. Prenatal chlamydial, gonococcal, and trichomonal screening in the Democratic Republic of Congo for case detection and management. *Int J STD AIDS*. 2020;31(3):221-229.  
[PubMed: PM31996095](#)
- Azevedo MJN, Nunes SDS, Oliveira FG, Rocha DAP. High prevalence of *Chlamydia trachomatis* in pregnant women attended at primary health care services in Amazon, Brazil. *Rev Inst Med Trop Sao Paulo*. 2019 Feb 14;61:e6.  
[PubMed: PM30785560](#)
- Suzuki S, Hoshi SI, Sekizawa A, et al. Current status of *Neisseria gonorrhoeae* cervicitis in pregnant women in Japan. *PLoS ONE*. 2019;14(2):e0211595.  
[PubMed: PM30730922](#)

## Economic Evaluations

No literature identified.

## Appendix — Further Information

### Previous CADTH Report

4. Screening for Chlamydia trachomatis and Neisseria gonorrhoeae during pregnancy: a health technology assessment. (*CADTH Health technology assessment*). Ottawa (ON): CADTH; 2018: <https://cadth.ca/screening-chlamydia-trachomatis-and-neisseria-gonorrhoeae-during-pregnancy-health-technology>. Accessed 2020 Jun 26.

### Systematic Review – Alternative Outcome

5. Azami M, Badfar GH, Mansouri A, et al. Prevalence of Chlamydia trachomatis in pregnant Iranian women: a systematic review and meta-analysis. *Int J Fertil Steril*. 2018;12(3):191-199.  
[PubMed: PM29935063](#)

### Non-Randomized Studies

#### *Alternative Comparator*

6. Bergquist EP, Trolard A, Kuhlmann AS, et al. Undertreatment of chlamydia and gonorrhea among pregnant women in the emergency department. *Int J STD AIDS*. 2020;31(2):166-173.  
[PubMed: PM31865863](#)

#### *Alternative Outcome*

7. Cho T, Aoki S, Saigusa Y, et al. Risk Factors for Chlamydia trachomatis infection and preterm birth in pregnant Japanese women: does chlamydial infection cause preterm birth? *Jpn J Infect Dis*. 2020;73(3):210-213.  
[PubMed: PM32009052](#)

#### *No Comparator*

8. Medina-Marino A, Mudau M, Kojima N, et al. Persistent Chlamydia trachomatis, Neisseria gonorrhoeae or Trichomonas vaginalis positivity after treatment among human immunodeficiency virus-infected pregnant women, South Africa. *Int J STD AIDS*. 2020;31(4):294-302.  
[PubMed: PM32089090](#)
9. Morikawa E, Mudau M, Olivier D, et al. Acceptability and feasibility of integrating point-of-care diagnostic testing of sexually transmitted infections into a South African antenatal care program for HIV-infected pregnant women. *Infect Dis Obstet Gynecol*. 2018;2018:3946862.  
[PubMed: PM29861622](#)
10. Pourabbas B, Rezaei Z, Mardaneh J, Shahian M, Alborzi A. Prevalence of Chlamydia trachomatis and Neisseria gonorrhoeae infections among pregnant women and eye colonization of their neonates at birth time, Shiraz, Southern Iran. *BMC Infect Dis*. 2018;18(1):477.  
[PubMed: PM30249196](#)

11. Wynn A, Ramogola-Masire D, Gaolebale P, et al. Prevalence and treatment outcomes of routine Chlamydia trachomatis, Neisseria gonorrhoeae and Trichomonas vaginalis testing during antenatal care, Gaborone, Botswana. *Sex Transm Infect.* 2018;94(3):230-235.  
[PubMed: PM29097418](#)

## *Testing Method Not Specified*

12. Goggins ER, Chamberlain AT, Kim TG, Young MR, Jamieson DJ, Haddad LB. Patterns of screening, infection, and treatment of Chlamydia trachomatis and Neisseria gonorrhea in pregnancy. *Obstet Gynecol.* 2020;135(4):799-807.  
[PubMed: PM32168225](#)
13. Warr AJ, Pintye J, Kinuthia J, et al. Sexually transmitted infections during pregnancy and subsequent risk of stillbirth and infant mortality in Kenya: a prospective study. *Sex Transm Infect.* 2019;95(1):60-66.  
[PubMed: PM30228109](#)
14. Shannon CL, Bristow C, Hoff N, et al. Acceptability and feasibility of rapid chlamydial, gonococcal, and trichomonal screening and treatment in pregnant women in 6 low- to middle-income countries. *Sex Transm Dis.* 2018;45(10):673-676.  
[PubMed: PM29528996](#)

## Review Article

15. Lochner HJ 3rd, Maraqa NF. Sexually transmitted infections in pregnant women: integrating screening and treatment into prenatal care. *Paediatr Drugs.* 2018;20(6):501-509.  
[PubMed: PM30128814](#)